Release date: 31 May 2013
Promoter – Financial Intermediary
H. LUNDBECK A/SLocation
Description
Financing Lundbeck’s Neurology R&D for the 2013-2015 period for the development of new innovative patented drugs for the treatment of CNS diseases with high unmet medical need.
Objectives
The project concerns the research and development (R&D) activities oriented towards disorders of the central nervous system including Parkinson’s and Alzheimer ’s disease, whereby a defect of the synaptic transmission within the nerve cells is a cause of the disease. It covers different stages of development including pre-clinical and clinical studies.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 150 million
Total cost (Approximate amount)
EUR 392 million
Environmental aspects
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorized for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement.
Status
Signed - 23/10/2013